Celcuity presents updated results from PIK3CA WT cohort of VIKTORIA-1 trial at 2025 SABCS. Study covers HR+, HER2- patients with ABC, following progression on CDK4/6 inhibitor.
On December 11, 2025, Celcuity Inc. (Nasdaq: CELC) disclosed fresh findings from the Phase 3 VIKTORIA-1 trial for gedatolisib, a PAM inhibitor, aimed at developing targeted therapies for oncology. The trial, focused on adults with HR+, HER2-, PIK3CA WT, ABC post-treatment with CDK4/6 and aromatase inhibitors, revealed promising outcomes. The updates were shared at the 2025 San Antonio Breast Cancer Symposium. These results mark a significant step in advancing treatment for this patient population.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments